Company & Sponsor Intelligence
NYU Langone Health
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials2
Recruiting0
Completed2
Countries1
Therapeutic footprint
alzheimersepilepsy
Indexed studies
NCT02635035Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT
adhd · United StatesPHASE2
adhd · United StatesPHASE2
NCT03254680Turmeric as Treatment in Epilepsy
epilepsy · United StatesNA
epilepsy · United StatesNA
NCT02347202Tools for Distance Delivery of an Evidence-based AD Family Caregiver Intervention
alzheimers · United StatesNA
alzheimers · United StatesNA
NCT02565966Understanding the Mechanism(s) of Action on the Modified Atkins Diet for Epilepsy: Human Brain Tissues
epilepsy · United StatesNA
epilepsy · United StatesNA
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →